India now has its first approved dengue vaccine. On 21 July 2026, the Central Drugs Standard Control Organisation (CDSCO) granted marketing authorisation for Qdenga (TAK-003) for prevention of dengue disease in people aged 4–60 years.
That is important—but “approved for ages 4–60” does not mean that every person in that age range should automatically receive it. India’s regulatory indication and WHO’s population-level recommendation answer different questions.
Quick answer: Qdenga is a live, attenuated tetravalent vaccine given as two 0.5 mL injections under the skin, at month 0 and month 3. India has authorised it for ages 4–60. WHO recommends routine programme use mainly for children aged 6–16 in places with high dengue transmission. An individual decision should consider age, local dengue burden, previous dengue exposure, pregnancy, breastfeeding, immune status, medicines and the ability to complete both doses.
India approval and WHO recommendation: why are the ages different?
| Question | Current answer | What it means for a patient |
|---|---|---|
| What has India approved? | CDSCO authorised Qdenga for prevention of dengue in people aged 4–60 years, with two doses at 0 and 3 months. | A licensed clinician may consider it within this age range, subject to the approved product information and the person’s health. |
| What does WHO recommend for routine public programmes? | WHO recommends TAK-003 mainly for children aged 6–16 years in locations with high dengue transmission. | This is a public-health targeting recommendation, not a statement that everyone aged 4–60 needs vaccination. |
| What about ages 4–5? | They are inside India’s approved label. WHO does not recommend programme use below age 6 because efficacy was lower and previous dengue exposure is usually less common. | Approval and programme priority differ; the benefit–risk decision needs an individual paediatric assessment. |
| What about adults aged 17–60? | They are inside India’s approved label, but outside WHO’s main routine-programme age band. WHO says some people with comorbidities in endemic countries may be considered within ages 6–60 when country-specific severe-dengue burden supports it. | Adult vaccination is not an automatic rule. Previous dengue, local epidemiology, comorbidities and exposure risk matter. |
| What about people over 60? | They are outside India’s authorised age range and available evidence is limited. | Do not use an internet article to extend the age indication. |
Marketing authorisation also does not by itself mean that the vaccine is already included in India’s Universal Immunisation Programme, supplied free of cost, or stocked at every clinic. Availability, programme policy and price must be checked with an authorised vaccination service. This website does not claim current vaccine stock.
What is Qdenga?
Qdenga is a live, attenuated tetravalent vaccine. “Tetravalent” means it contains weakened vaccine viruses representing all four dengue serotypes: DENV-1, DENV-2, DENV-3 and DENV-4. It uses a DENV-2 strain as the genetic backbone.
It is a preventive vaccine. It does not treat current dengue, raise platelets during an acute illness or replace clinical monitoring.
Schedule that matters
- Dose 1: month 0.
- Dose 2: 3 months after the first dose.
- Do not deliberately shorten the interval.
- If the second dose is delayed, WHO says the series does not need to be restarted; give the missing dose at the next appropriate opportunity after clinical review.
- A febrile or significant acute illness may require postponement until recovery.
Protection is not immediate and no dengue vaccine prevents every infection. Plan vaccination early enough to complete the course rather than seeking a last-minute injection during an outbreak or just before travel.
How effective is it? Long-term numbers, not advertising claims
The pivotal TIDES phase 3 trial enrolled more than 20,000 children and adolescents aged 4–16 in dengue-endemic countries. Results change with follow-up duration, previous dengue exposure and circulating serotype, so one percentage cannot describe every person.
At about 57 months after the first dose, WHO’s evidence review reported:
| Outcome | Overall vaccine efficacy | Previously dengue-exposed (seropositive) | No evidence of previous dengue (seronegative) |
|---|---|---|---|
| Virologically confirmed dengue | 61.2% | 64.2% | 53.5% |
| Dengue requiring hospitalisation | 84.1% | 85.9% | 79.3% |
These are relative reductions observed in a trial population, not a guarantee for an individual. The evidence was strongest and most consistent against DENV-1 and DENV-2. Among participants who were seronegative before vaccination, efficacy against DENV-3 and DENV-4 was not demonstrated reliably because estimates were imprecise and case numbers were limited.
That uncertainty is one reason WHO does not recommend programme use in low- or moderate-transmission settings until the efficacy–risk profile for DENV-3 and DENV-4 in seronegative people is clearer.
What does “high dengue transmission” mean?
WHO advises countries to use population data—not one person’s CBC or one season’s case count. Indicators may include:
- dengue antibodies in more than 60% of children by age 9; or
- the average age at which dengue hospitalisations peak being below 16 years.
These are public-health indicators. A family cannot determine them from a neighbourhood WhatsApp message, a single positive NS1 result or the fact that dengue occurs every monsoon. We should not assume that Patna or any other district meets the WHO programme threshold unless reliable local surveillance data and public-health policy support that conclusion.
Is a previous dengue blood test required before Qdenga?
Qdenga is different from the older vaccine Dengvaxia (CYD-TDV), for which prior dengue infection was crucial because vaccination of dengue-naïve people raised safety concerns. That history is why many people have heard that “a dengue test is compulsory before every dengue vaccine.”
For TAK-003, WHO does not recommend a pre-vaccination screening strategy when introducing the vaccine in a high-transmission programme. However:
- prior laboratory-confirmed dengue can still be relevant to an individual benefit–risk discussion;
- NS1 and IgM tests used during acute illness are not simple lifetime “dengue history” tests;
- antibody tests can cross-react with other flaviviruses and must be interpreted carefully; and
- low-transmission settings require extra caution because of uncertainty in seronegative people, especially for DENV-3 and DENV-4.
Do not order a random dengue test solely to make this decision without first discussing what the result can and cannot show.
Who should not receive Qdenga?
Because it is a live vaccine, WHO and current product information say it should not be given to:
- a person who had a severe allergic reaction to a previous dose or a vaccine component;
- someone who is pregnant or planning pregnancy within at least one month after vaccination;
- someone who is breastfeeding;
- a person with congenital or acquired immune deficiency;
- someone receiving immunosuppressive treatment such as chemotherapy or high-dose systemic corticosteroids; or
- a person with symptomatic HIV infection, or asymptomatic HIV with impaired immune function.
Timing around immune-suppressing medicines must be decided by the treating specialist. Do not stop steroids, chemotherapy or another important treatment to obtain a vaccine.
Common reactions and the uncommon safety signal
In pooled clinical data for ages 4–60, current European product information reports the following common reactions:
| Reaction | Approximate frequency |
|---|---|
| Injection-site pain | 50% |
| Headache | 35% |
| Muscle pain | 31% |
| Injection-site redness | 27% |
| Feeling unwell | 24% |
| Weakness | 20% |
| Fever | 11% |
They usually began within two days, were mild to moderate, lasted around one to three days and occurred less often after dose 2.
WHO safety surveillance from Brazil reported 124 anaphylaxis cases among about 2.88 million Qdenga doses administered up to September 2024—approximately 36.4 per million doses. Most began soon after vaccination. Vaccination should therefore take place where staff can recognise and treat anaphylaxis, with the usual post-vaccination observation and adverse-event reporting systems.
Seek urgent care for breathing difficulty, facial or tongue swelling, widespread hives, collapse, or other signs of a severe allergic reaction after vaccination.
A practical decision checklist for a clinic visit
Bring or be ready to discuss:
- Age and whether the person falls within India’s authorised range.
- Pregnancy or breastfeeding status and near-term pregnancy plans.
- Immune conditions and medicines, especially steroids, biologics, chemotherapy or transplant medicines.
- Any previous laboratory-confirmed dengue, including the approximate year and severity.
- Residence, repeated travel and likely dengue exposure, not just one planned trip.
- Whether both doses can be completed three months apart.
- Previous serious vaccine allergy or fainting after injections.
- Current fever or acute illness.
The decision should end with a documented product, dose, batch, date and plan for dose 2—not merely “dengue injection taken.”
What vaccination does not replace
Even after two doses:
- continue daytime mosquito-bite prevention;
- remove standing water and control Aedes breeding sites;
- do not dismiss a new fever as “impossible dengue”;
- avoid aspirin and NSAIDs such as ibuprofen when dengue is suspected until clinically assessed; and
- seek urgent care for warning signs such as severe abdominal pain, persistent vomiting, bleeding, breathing difficulty, cold clammy skin, unusual drowsiness or reduced urine.
Other dengue vaccines: avoid name confusion
| Vaccine | Current relevance |
|---|---|
| Qdenga / TAK-003 | First dengue vaccine granted marketing authorisation in India, July 2026; two-dose live vaccine. |
| Dengvaxia / CYD-TDV | Older three-dose vaccine associated with the need to confirm previous dengue infection; discontinued in the United States and not the vaccine newly approved in India. |
| DengiAll / TV003-derived candidate | An Indian single-dose candidate being studied in a large phase 3 trial; an investigational vaccine is not the same as an approved product. |
| Butantan-DV / TV003-derived vaccine | A separate single-dose vaccine developed in Brazil; it should not be confused with Qdenga or India’s investigational DengiAll programme. |
Bottom line
Qdenga is a real and important advance, but the useful question is not simply “Is there a dengue vaccine?” It is: does the expected benefit outweigh the limitations for this person, in this place, at this age and with this immune status?
India’s approval provides a legal age range of 4–60 years. WHO’s narrower 6–16-year recommendation identifies where population benefit is most clearly supported. A clinician should connect those two facts to the patient’s individual risks rather than offering the vaccine as a universal monsoon injection.
Medical references
- Government of India, PIB: CDSCO approves India’s first dengue vaccine, 21 July 2026
- WHO position paper on dengue vaccines, May 2024
- WHO: Vaccines and immunization—Dengue questions and answers
- WHO Global Advisory Committee on Vaccine Safety: Dengue vaccines
- CDC: Dengue vaccines for health care providers, updated September 2026
- EMA: Qdenga product information, updated September 2026
- TIDES phase 3 trial: efficacy of TAK-003 in children and adolescents
- ICMR annual report 2024–25: DengiAll phase 3 milestone
This article is for health education and does not replace an individual medical consultation. Symptoms, test results, medicines, and treatment decisions should be discussed with a qualified clinician.
Seek urgent medical care for severe breathing difficulty, chest pain, confusion, fainting, uncontrolled bleeding, severe dehydration, or rapidly worsening symptoms.